focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Half Yearly Report

31 Dec 2009 07:00

RNS Number : 8588E
ViaLogy PLC
31 December 2009
 



ViaLogy PLC ("ViaLogy" or "the Company")

Interim Report and Unaudited accounts for six months ended 30 September 2009

Chairman's statement for the six months ended 30 September 2009

The Interim Report covers the six-month period to 30 September 2009. The figures show a loss for the period of £2,558,136 which includes £1,430,181 for amortisation and depreciation. The amortisation charges relate to the value of ViaLogy's Intellectual Property and associated research and development, which is amortised over a period of six years. The cash outflow from operations during the period was £1,240,391.

During the period ViaLogy raised a total of £3,620,092 before expenses. On 5 May £1,637,500 before expenses was raised by conversion of warrants.  A placing of 49,564,800 new shares on 18 August raised a further £1,982,592 before expenses.

As you will see from the CEO's Review, we are pleased to confirm that ViaLogy has made considerable progress during 2009. It is barely 18 months since the company commenced proof-of-concept trials for its QuantumRD oil & gas exploration data analysis product. We can claim two consecutive successful wells in 2009 (a planned third well was postponed due to an Operator's lease problem, but will be started early in the New Year), and multiple wells are planned for Q1 2010 and beyond.

Importantly, during the last six months, we have developed a growing list of contracted new customers for QuantumRD, and have signed a total of eight Master Services Agreements with experienced oil exploration and production companies. We have already completed work for a number of these businesses; our recommendations for well locations, often in very challenging formations, have been accepted and drilling is scheduled for Q1 2010 and beyond. These orders lead me to the firm belief that the coming year should produce a growing revenue stream for ViaLogy. Our CEO reminds us that we cannot guarantee 100 per cent success every time, and that the technology is being developed and refined as we gain experience with different and often difficult types of formations. Nor can we influence our clients' drilling dates. But the fact that knowledgeable and experienced clients have placed their confidence in us and our QuantumRD analysis bolsters our belief that our unique active signal processing technology applied to seismic and other digital exploration data will, over time, substantially reduce the incidence of 'dry holes' and can have a significant financial impact on the industry. 

Our activities to date have been concentrated on North American sites, but I can report that the potential of QuantumRD has attracted attention and enquiries from global companies that have expressed interest in the technology to enhance their exploration results. Discussions have been held and we are considering cooperation activities. However, our focus is maintaining our performance for our direct clients.

I would like to thank all ViaLogy's loyal investors for their patience and continued confidence. We will continue to do our best to justify it.

Terry Bond

Chairman

ViaLogy PLC

31 December 2009

Enquiries: 

ViaLogy PLC

01235 834734

Terry Bond, Chairman

Seymour Pierce Limited

020 7107 8000

Mark Percy/Catherine Leftley

Chief Executive Officer's review 

Over the previous six months we have focused the company's attention almost entirely on our QuantumRD hydrocarbon reservoir discovery and characterization product and its target market of oil exploration and production firms. As of September 30, ViaLogy was credited with having determined drilling locations for two successful wells. To date, we have eight active clients who are scheduled to drill a number of wells at our recommended locations prior to March 31, 2010, the end of our Fiscal Year. Our goal of course is to produce as many successful wells as possible, and as rapidly as possible, but we do not control the timing of our clients' drilling. Nor will our locations prove successful in all cases, something that is understood by our clients. Nevertheless, as we are told regularly, increasing their success rate and reducing the number of costly dry holes would have an enormous business impact. We now have a contingent order book of fifty plus wells, ie work under contract in which well locations will be determined by QuantumRD, and delivered to current clients. The decision to drill and its timing are in the hands of the client. We also have a strong sales pipeline of prospective customers. Our business model, based on an up-front service fee and a success fee calculated as a working interest in the well, is finding acceptance in the target client base; although in a few cases we have foregone a success fee pending a successful demonstration of the technology on client wells. This should lead to long term client partnerships. We are on target with our internal operating and financial plans; we have a full workload and we are evaluating and hiring key technical staff in the form of experienced geophysicists; and we are trying to meet demand to expand the business - which is limited by our resources.

Our QSUB product, the application of our core quantum resonance interferometry technology to airborne synthetic aperture radar in order to locate and identify buried objects, has performed very well in challenging field tests. We will develop a concentrated effort to bring it to market when we have sufficient resources. As for our Sensor Policy Manager software product, we are actively exploring strategic alternatives including divestiture, licensing and technology partnerships. Here again, given our focus on the energy industry, we do not have resources to continue to develop and market this remarkable capability.

Robert W. Dean

Chief Executive Officer

ViaLogy PLC

31 December 2009

Consolidated income statement for the six months ended 30 September 2009

Unaudited

Unaudited

Audited

6 months

6 months

Year to 

to 30 Sep 

to 30 Sep 

to 31 Mar 

Notes

2009

2008

2009

£

£

£

Unaudited

Unaudited

Audited

6 months

6 months

Year to 

to 30 Sep 

to 30 Sep 

to 31 Mar 

Notes

2009

2008

2009

£

£

£

Revenue

2

11,266

32,444

129,028

Cost of sales

-

10,587

12,369

--------

--------

--------

Gross profit

2

11,266

21,857

116,659

Share based payments

216,397

338,685

1,068,953

Depreciation and amortisation

1,430,181

1,203,630

2,761,158

Other administrative expenses

1,168,265

1,310,869

2,510,311

Administrative expenses 

2,814,843

2,853,184

6,340,422

--------

--------

--------

Loss from operations

(2,803,577)

(2,831,327)

(6,223,763)

Finance income

369

32,128

43,006

--------

--------

--------

Loss for the year before taxation 

(2,803,208)

(2,799,199)

(6,180,757)

--------

--------

--------

Taxation

3

245,072

202,097

424,345

--------

--------

--------

Loss for the year attributable to equity 

holders of the parent

2

(2,558,136)

(2,597,102)

(5,756,412)

--------

--------

--------

Loss per share

Basic and diluted

4

(0.43)p

(0.55)p

(1.183)p

  Consolidated statement of changes in equity for the six months ended 30 September 2009

Share

Share 

Warrant

Foreign

Retained

Total

capital

premium

reserve

exchange

earnings

account

reserve

At 1 April 2009

5,037,736

15,705,702

387,500

2,678,831

(13,124,562)

10,685,207

Loss for period

-

-

-

-

(2,558,136)

(2,558,136)

Exchange differences arising on 

translation of foreign operations

-

-

-

354,395

-

354,395

--------

--------

--------

--------

--------

--------

Total income and expense 

-

-

-

354,395

(2,558,136)

(2,203,741)

recognised for the year

Arising on issue of shares

1,253,183

2,608,237

(379,375)

-

-

3,482,045

Share options expense

-

-

-

-

216,397

216,397

--------

--------

--------

--------

--------

--------

Balance at 30 September 2008

6,290,919

18,313,939

8,125

3,033,226

(15,466,301)

12,179,908

--------

--------

---- ----

--------

--------

--------

  Consolidated balance sheet at 30 September 2009

Unaudited

Unaudited

Audited

30 Sep 

30 Sep 

31 Mar 

2009

2008

2009

£

£

£

Assets

Non current assets

Property, plant and equipment

402,753

149,995

166,806

Intangible Assets

10,797,064

10,456,844

12,095,841

Financial Assets

200,000

200,000

200,000

--------

--------

--------

11,399,817

12,462,647

--------

--------

--------

Current assets

Inventories

14,233

12,469

15,945

Trade and other receivables 

54,040

49,272

15,597

Cash and cash equivalents

2,422,685

1,961,491

432,190

--------

--------

--------

2,490,958

463,732

--------

--------

--------

Total Assets

13,890,775

12,830,071

12,926,379

--------

--------

--------

Liabilities

Current liabilities

Trade and other payables

166,985

317,451

240,177

Corporation tax liability

29,788

-

29,788

Non-current liabilities

Deferred tax liability

1,514,094

1,756,592

1,971,207

--------

--------

--------

Total liabilities

1,710,867

2,074,043

2,241,172

Capital and reserves attributable to equity

holders of the Company

Share capital

6,290,919

5,037,736

5,037,736

Share premium account

18,313,939

15,698,202

15,705,702

Warrant Reserve

8,125

387,500

387,500

Foreign Exchange translation reserve

3,033,226

328,110

2,678,831

Retained Earnings

(15,466,301)

(10,695,520)

(13,124,562)

--------

--------

--------

Shareholders' funds

12,179,908

10,685,207

--------

--------

--------

Total equity and liabilities

13,890,775

12,830,071

12,926,379

--------

--------

--------

  Consolidated cash flow statement for six months ended 30 September 2009

Unaudited

Unaudited

Audited

30 Sep 

30 Sep 

31 Mar 

2009

2008

2009

£

£

£

Operating activities

Loss before tax

(2,803,208)

(2,799,199)

(6,180,757)

Adjustments for :-

Finance income

(369)

(32,128)

(43,006)

  Depreciation

38,049

27,025

63,570

Amortisation

1,392,132

1,176,605

2,697,588

Share option expense

216,397

338,685

1,068,953

Foreign exchange movements

26,162

(7,109)

(187,804)

--------

--------

--------

Operating activities before changes in working capital

(1,130,837)

(1,296,121)

(2,581,456)

Reduction/(increase) in trade and other receivables

(38,443)

(20,156)

13,519

Increase in inventories

1,712

(1,954)

(5,430)

(Reduction)/increase in trade and other payables

(73,192)

(62,795)

(52,859)

Interest received

369

32,128

43,006

Interest paid

-

-

-

--------

--------

--------

Cash generated from operations

(1,240,391)

(1,348,898)

(2,583,220)

Investing activities

Internally generated intangible asset

(271,711)

(535,255)

(997,859)

Acquisition of tangible fixed assets

(293,984)

(93,406)

(106,991)

--------

--------

--------

(565,695)

(628,661)

(1,104,850)

Financing activities

Cash inflow from issue of new shares

3,620,092

1,800,000

1,800,000

Share issue costs

(149,609)

(51,000)

(43,500)

Cash inflow from exercise of options

11,562

-

-

--------

--------

--------

3,482,045

1,749,000

1,756,500

Increase/(decrease) in cash and cash equivalents

1,675,959

(228,559)

(1,931,570)

Foreign exchange differences on translation of cash and cash equivalents.

314,536

-

173,710

Cash and cash equivalents at beginning of period

432,190

2,190,050

2,190,050

--------

--------

--------

Cash and cash equivalents at end of period

2,422,685

1,961,491

432,190

--------

--------

--------

  Notes forming part of the parent company financial statements

Accounting policies

Basis of preparation

The financial information has been prepared in accordance with International Financial Reporting Standards (IFRS) and stated in British pounds (£). In preparing the interim financial statements, the same accounting policies are applied as in the preparation of the audited Financial Statements for the year ended 31 March 2009 except for the changes set out below.

The above financial information does not constitute statutory accounts within the meaning of Section 240, Companies Act 1985. The information relating to the six months ended 30 September 2009 has been reviewed but not audited. Information relating to the year ended 31 March 2009 has been extracted from the statutory accounts of the Group which have been audited by the Group's auditors BDO Stoy Hayward and whose report thereon is unqualified. 

Going concern

The Group's financial plans require the Group to secure a number of sales contracts over the course of the coming year in order to fund the working capital requirements and the development programme of the Group. 

As at 30 September 2009 the Group have signed contracts with six customers and a contingent backlog of more than 40 wells. The board are confident that more contracts will be forthcoming based on the strong sales pipeline which has been developed. 

In the event that these sales contracts are not received in line with the Group's financial plans then Directors are confident that further equity funding could be raised or expenditure could be sufficiently reduced to ensure that funds are available to meet working capital requirements. Accordingly the Group's financial statements have been prepared on a going concern basis.

2. Segmental analysis 

 

The Group's primary and secondary formats for reporting segment information are shown below. The primary operations segment is based in the USA; the head office primary segment is based in the UK. The differing geographical locations being the secondary segment overlap completely with the differing nature of the business segments.

2009 Business Segments

Operations

Head Office

Unallocated

Consolidated

£

£

£

£

Revenue

11,266

-

-

11,266

--------

--------

--------

--------

Gross profit

11,266

-

-

11,266

Net finance income

-

-

369

369

Net tax credit

-

-

245,072

245,072

Net loss for the period

(2,549,914)

(253,663)

245,441

(2,558,136)

Segment assets

10,044,375

2,331,946

1,514,094

13,890,775

Segment liabilities

102,137

94,636

1,514,094

1,710,867

--------

--------

--------

--------

Costs to acquire plant property and equipment

90,416

203,568

-

293,984

Costs to acquire intangible assets

271,711

-

-

271,711

Depreciation and amortisation

1,429,440

741

-

1,430,181

Share based payments charged

-

216,397

-

216,397

--------

--------

--------

--------

All sales were to external customers.

2008 Business Segments

Operations

Head Office

Unallocated

Consolidated

£

£

£

£

Revenue

32,444

-

-

32,444

--------

--------

--------

--------

Gross profit

21,857

-

-

21,857

Net finance income

-

-

32,128

32,128

Net tax credit

-

-

202,097

202,097

Net loss for the period

(2,272,618)

(558,709)

234,225

(2,597,102)

Segment assets

8,937,308

2,136,171

1,756,592

12,830,071

Segment liabilities

230,301

87,150

1,756,592

2,074,043

--------

--------

--------

--------

Costs to acquire plant property and equipment

93,406

-

-

93,406

Costs to acquire intangible assets

535,255

-

-

535,255

Depreciation and amortisation

1,202,974

656

-

1,203,630

Share based payments charged

-

338,685

-

338,685

--------

--------

--------

--------

All sales were to external customers.

3. Taxation on profits from ordinary activities

 

The movement on the tax account relates to the release of the provision on the deferred tax credit. The calculation is shown below: 

2009

2008

£

£

At 1 April

1,971,205

1,908,970

Release for the six months to 30 Sept

(245,072)

(202,094)

Foreign exchange translation

(212,038)

49,716

--------

--------

At 30 September 

1,514,095

1,756,592

--------

--------

Deferred tax is calculated in full on temporary differences under the liability method using a tax rate of 35%.

4. Loss per share

 

Basic

The calculation of earnings per share is based on the loss for the period of £2,558,136 (2008 - loss £2,597,102) and on 602,470,355 (2008 - 503,125,537) ordinary shares, being the weighted average number of ordinary shares in issue during the period.

Diluted

Diluted earnings per share dilute the basic earnings per share to take into account share options and warrants. The calculation includes the weighted average number of ordinary shares that would have been issued on the conversion of all the dilutive share operations and warrants into ordinary shares. 75,231,139 options and 2,006,154 warrants have been excluded from this calculation as this would reduce the loss per share.

5. Share capital

Authorised

2009

2008

2009

2008

Number

Number

£

£

Ordinary Shares of 1p Each

750,000,000

750,000,000

7,500,000

750,000,000

 
Authorised
 
2009
2008
2009
2008
 
__________
__________
__________
__________
 
 
 
 
 
 
Allotted, called up and fully paid
 
2009
2008
2009
2008
 
Number
Number
£
£
Ordinary Shares of 1p Each
 
 
 
 
At 1 April 
503,773,621
458,773,620
5,037,736
4,587,736
Shares issued for cash
50,377,300
45,000,000
503,773
450,000
Employee Share option exercised
753,476
-
7,534
-
Warrants converted into shares
74,187,500
-
741,875
-
 
 
 
 
 
At 30 September
629,091,897
503,773,621
6,290,918
5,037,736
 
__________
__________
__________
__________

The Group raised £1.63 million, (£1.62 million net of expenses), on 5 May 2009 via:-

the conversion of 26,687,500 warrants at 2.5p per warrant;

the conversion of 47,500,000 warrants at 2.0p per warrant ;and

the issue of 812,500 shares at 4p per share.

The Group also raised a further £1.99 million (£1.91 million net of expenses) via a private placing of 49,564,800 shares at 4 pence per share on 18 August 2009.

 

6. Reserves

2009

Ordinary share

 capital

Share 

Premium account

Warrant

Scheme 

reserve

Foreign Exchange 

Retained

earnings 

£

£

£

£

£

At 1 April 2009

5,037,736

15,705,702

387,500

2,678,831

(13,124,562)

Arising on issue of shares 

1,253,183

2,757,846

(379,375)

-

-

Fundraising costs

-

(149,609)

-

-

-

Loss for the period

-

-

-

-

(2,558,136)

Arising in the period

-

-

-

354,395

-

Share option expense

-

-

-

-

216,397

--------

--------

--------

--------

--------

At 30 September 2009

6,290,919

18,313,939

8,125

3,033,226

(15,466.301)

_________

_________

_________

_________

_________

 

The following describes the nature and purpose of each reserve within shareholders equity:

Reserve
 
Description and purposes
 
 
 
Share premium account
 
Amount subscribed for share capital in excess of nominal value.
 
 
 
Retained earnings
 
Cumulative net gains and losses recognised in the consolidated income statement.
 
 
 
Foreign Exchange
 
Exchange difference arising on translation of foreign operations.

 

2008

Ordinary share

 capital

Share 

Premium 

account

Warrant

Scheme 

reserve

Foreign Exchange 

Retained

earnings 

£

£

£

£

£

At 1 April 2008

4,587,736

14,511,702

275,000

(436,394)

(8,437,103)

Arising on issue of shares 

450,000

1,237,500

112,500

-

-

Fundraising costs

-

(51,000)

-

-

-

Loss for the period

-

-

-

-

(2,597,102)

Arising in the period

-

-

-

764,504

-

Share option expense

-

-

-

-

338,685

-------

-------

--------

--------

--------

At 30 September 2008

5,037,736

15,698,202

387,500

328,110

(10,695,520)

_________

_________

_________

_________

_________

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR EAKAEDLKNFFE
Date   Source Headline
11th Sep 20237:00 amRNSCancellation - Yourgene Health plc
11th Sep 20237:00 amRNSDe-listing and cancellation of trading of Shares
8th Sep 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
8th Sep 202311:23 amRNSScheme of Arrangement becomes Effective
8th Sep 20239:54 amRNSForm 8.5 (EPT/RI)
8th Sep 20237:30 amRNSSuspension - Yourgene Health Plc
7th Sep 202311:46 amRNSCourt sanction of the Scheme of Arrangement
7th Sep 202310:10 amRNSForm 8.5 (EPT/RI)
5th Sep 202310:30 amRNSForm 8.5 (EPT/RI)
4th Sep 202310:01 amRNSForm 8.5 (EPT/RI)
1st Sep 20235:30 pmRNSYourgene Health
1st Sep 202312:07 pmRNSForm 8.5 (EPT/RI)
31st Aug 202310:58 amRNSForm 8.3 - Yourgene Health PLC
31st Aug 20239:42 amRNSForm 8.5 (EPT/RI)
30th Aug 20239:42 amRNSForm 8.5 (EPT/RI)
24th Aug 20239:27 amRNSForm 8.5 (EPT/RI) - Yourgene Health PLC
23rd Aug 20239:50 amRNSForm 8.5 (EPT/RI)
23rd Aug 20239:24 amRNSForm 8.3 - Yourgene Health PLC
22nd Aug 20231:25 pmRNSHolding(s) in Company
22nd Aug 20239:01 amRNSForm 8.5 (EPT/RI)
21st Aug 20235:29 pmRNSForm 8.3 - Yourgene Health plc
21st Aug 20232:12 pmRNSForm 8.3 - Yourgene Health plc
21st Aug 202311:03 amRNSForm 8.5 (EPT/RI) - Yourgene Health PLC
21st Aug 20237:02 amRNSForm 8.3 - Yourgene Health PLC
18th Aug 20233:09 pmRNSForm 8.3 - Yourgene Health plc
18th Aug 20231:28 pmRNSForm 8.5 (EPT/RI)
17th Aug 20235:03 pmRNSResult of Court Meeting and General Meeting
17th Aug 202310:13 amRNSForm 8.5 (EPT/RI)
16th Aug 20239:40 amRNSForm 8.5 (EPT/RI)
15th Aug 20234:41 pmRNSForm 8.5 (EPT/RI) Replacement
15th Aug 202312:00 pmRNSForm 8.5 (EPT/RI)
14th Aug 202310:16 amRNSForm 8.5 (EPT/RI)
14th Aug 20239:20 amRNSForm 8.3 - Yourgene Health PLC
11th Aug 20231:12 pmRNSForm 8.3 - Yourgene Health plc
11th Aug 202310:10 amRNSForm 8.5 (EPT/RI)
10th Aug 202311:59 amRNSForm 8.5 (EPT/RI)
9th Aug 202310:12 amRNSForm 8.5 (EPT/RI)
8th Aug 20231:57 pmRNSForm 8.3 - Yourgene Health plc
8th Aug 202311:43 amRNSForm 8.5 (EPT/RI)
7th Aug 20231:57 pmRNSForm 8.3 - Yourgene Health plc
7th Aug 202311:56 amRNSForm 8.5 (EPT/RI)
4th Aug 20231:35 pmRNSForm 8.3 - Yourgene Health plc
4th Aug 202310:54 amRNSForm 8.5 (EPT/RI)
4th Aug 202310:47 amRNSForm 8.3 - Yourgene Health PLC
3rd Aug 202310:04 amRNSForm 8.5 (EPT/RI)
3rd Aug 20239:51 amRNSForm 8.3 - Yourgene Health PLC
3rd Aug 20239:19 amRNSForm 8.3 - YOURGENE HEALTH PLC
2nd Aug 20232:02 pmRNSForm 8.3 - Yourgene Health plc
2nd Aug 202310:21 amRNSForm 8.5 (EPT/RI)
1st Aug 20235:30 pmRNSForm 8.5 (EPT/RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.